Skip to main content
Rural Health Information Hub

FDA: Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability

Federal Register
Mar 11, 2024
Notice from the Food and Drug Administration (FDA) announcing the revocation of one Emergency Use Authorization (EUA) issued to Eli Lilly and Co. (Lilly) for bamlanivimab and etesevimab administered together. The revocation is effective December 14, 2023.
Tagged as
COVID-19 · Legislation and regulations · Pharmacy and prescription drugs